Skip to main content

Table 1 Baseline characteristics of the study population

From: Prediction of residual ischemic risk in ticagrelor-treated patients with acute coronary syndrome

Characteristics Derivation group
(n = 336)
Validation group
(n = 415)
Age, (mean ± SD) y 68.67 ± 6.61 58.28 ± 10.13
Male sex, n (%) 232 (69.05) 328 (79.04)
BMI, (mean ± SD) kg/m2 25.34 ± 3.33 25.94 ± 3.56
Cardiovascular risk factors
 Smoking, n (%) 139 (41.37) 238 (57.35)
 Hypertension, n (%) 220 (65.48) 241 (58.07)
 Hyperlipidemia, n (%) 103 (30.65) 121 (29.16)
 Diabetes mellitus, n (%) 112 (33.33) 151 (36.39)
Other medical history
 Prior MI, n (%) 52 (15.48) 106 (25.54)
 Prior PCI, n (%) 71 (21.13) 108 (26.02)
 Prior CABG, n (%) 4 (1.19) 3 (0.72)
 Arrhythmia, n (%) 24 (7.14) 17 (4.10)
Clinical diagnosis
 STEMI, n (%) 35 (10.42) 35 (8.43)
 NSTEMI, n (%) 25 (7.44) 29 (6.99)
 UA, n (%) 231 (68.75) 270 (65.06)
 Undergoing PCI, n (%) 179 (53.27) 368(88.67)
Number of diseased vessels
 1-vessel disease, n (%) 44 (13.10) 129 (31.08)
 2-vessel disease, n (%) 42 (12.50) 115 (27.71)
 3-vessel disease, n (%) 92 (27.38) 80 (19.28)
Comorbidities
 Renal insufficiency, n (%) 14 (4.17) 10 (2.41)
 History of stroke, n (%) 29 (8.63) 30 (7.23)
Laboratory examination
 LVEF, median (IQR) % 58.00 (52.00,63.00) 58.00 (52.00,63.00)
 Creatinine, median (IQR) μ mol/L 79.55 (69.00,93.85) 78.80 (69.90,91.60)
Concomitant medication
 Tirofiban, n (%) 153 (45.54) 210 (50.60)
 PPI, n (%) 183 (54.46) 228 (54.94)
 Heparin, n (%) 161 (47.92) 172 (41.45)
  1. Abbreviations: BMI Body mass index, MI Myocardial infarction, PCI Percutaneous coronary intervention, CABG Coronary artery bypass grafting, NSTEMI Non-ST-segment elevation myocardial infarction, STEMI, ST-segment elevation myocardial infarction, UA Unstable angina, LVEF Left ventricular ejection fraction, PPI Proton Pump Inhibitor